Sugi Predict

Sugi Predict / Compounds / SCHEMBL972506

SCHEMBL972506

SCHEMBL972506

CCCOc1ccc(S(=O)(=O)N2CCC(O)CC2)cc1-c1nn2c(CCC)nc(C)c2c(=O)[nH]1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 20/20 0.73
▸ PDE1A P54750 6/20 0.73
▸ PDE1B Q01064 6/20 0.73
▸ PDE1C Q14123 6/20 0.73
▸ PDE4B Q07343 2/20 0.73
▸ PDE6A P16499 2/20 0.72
▸ PDE2A O00408 1/20 0.72
▸ PDE6D O43924 1/20 0.72
▸ PDE9A O76083 1/20 0.72
▸ CHRM2 P08172 1/20 0.72
▸ ADORA3 P0DMS8 1/20 0.72
▸ PDE6G P18545 1/20 0.72
▸ MAOA P21397 1/20 0.72
▸ PDE4A P27815 1/20 0.72
▸ ADORA1 P30542 1/20 0.72
▸ ADRA1A P35348 1/20 0.72
▸ PDE6B P35913 1/20 0.72
▸ PDE6C P51160 1/20 0.72
▸ SLC6A3 Q01959 1/20 0.72
▸ PDE4C Q08493 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5606 0.95 PDE5A (0.81) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL974182 0.93 PDE5A (0.72) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL973386 0.92 PDE5A (0.70) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL1456512 0.91 PDE5A (0.68) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL12822605 0.90 PDE5A (0.77) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL974583 0.90 PDE5A (0.89) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL973387 0.89 PDE5A (0.75) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL31347918 0.89 PDE5A (0.90) PDE5APDE1APDE1BPDE1CPDE4B
Hydrochloric Acid SCHEMBL974259 0.89 PDE5A (0.88) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL12822992 0.88 PDE5A (0.64) PDE5APDE1APDE1BPDE1CPDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9155691-B2 Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (KR) 2015-10-13 — — US claimed
US-20140179701-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2014-06-26 — — US claimed
EP-2556820-A2 COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES SK Chemicals, Co., Ltd. (KR) 2013-02-13 — — EP claimed
US-20130030174-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2013-01-31 — — US claimed
US-9155691-B2 Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (KR) 2015-10-13 — — US disclosed
US-20140179701-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2014-06-26 — — US disclosed
US-8716298-B2 Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (KR) 2014-05-06 — — US disclosed
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-03-07 — — US disclosed
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-03-07 — — US disclosed
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-03-07 — — US disclosed
EP-2556820-A2 COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES SK Chemicals, Co., Ltd. (KR) 2013-02-13 — — EP disclosed
US-20130030174-A1 COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR SK CHEMICALS CO., LTD. (KR) 2013-01-31 — — US disclosed
US-20040067945-A1 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors BAYER INTELLECTUAL PROPERTY GMBH (DE) 2004-04-08 — — US disclosed
EP-1392314-A1 NOVEL USE OF 2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONES Bayer HealthCare AG (DE) 2004-03-03 — — EP disclosed
US-6566360-B1 Administering 2-phenyl-substituted imidazotriazinones having short, unbranched alkyl radicals in the 9-position for therapy of hypertrophy of the prostate, incontinence or female sexual dysfunction in mammals BAYER AKTIENGESELLSCHAFT (DE) 2003-05-20 — — US disclosed
WO-2002089808-A1 NOVEL USE OF 2-PHENYL-SUBSTITUTED IMIDAZOTRIAZINONES BAYER HEALTHCARE AG (DE) 2002-11-14 — — WO disclosed
US-6362178-B1 TREATMENT OF CARDIOVASCULAR DIORDERS, CEREBROVASCULAR DISORDERS, UROGENITAL DISORDERS AND ERECTILE DYSFUNCTION BAYER AKTIENGESELLSCHAFT (DE) 2002-03-26 — — US disclosed
EP-1174431-A2 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors Bayer Aktiengesellschaft (DE) 2002-01-23 — — EP disclosed
EP-1049695-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER AG (DE) 2000-11-08 — — EP disclosed
WO-1999024433-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 1999-05-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE2A PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885
US-20040067945-A1 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors PDE3B, PDE3A, PDE2A PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.